Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 1
2010 3
2011 2
2012 2
2014 1
2015 5
2016 2
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Technosphere insulin: inhaled prandial insulin.
Setji TL, Hong BD, Feinglos MN. Setji TL, et al. Expert Opin Biol Ther. 2016;16(1):111-7. doi: 10.1517/14712598.2016.1121230. Epub 2015 Dec 11. Expert Opin Biol Ther. 2016. PMID: 26567896 Review.
INTRODUCTION: Insulin therapy is a mainstay for treatment of diabetes mellitus; however, many barriers to insulin exist. Insulin human inhalation powder (technosphere insulin) is a new FDA-approved alternative to subcutaneous bolus ins
INTRODUCTION: Insulin therapy is a mainstay for treatment of diabetes mellitus; however, many barriers to insulin exist. In
Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.
Bode BW, McGill JB, Lorber DL, Gross JL, Chang PC, Bregman DB; Affinity 1 Study Group. Bode BW, et al. Diabetes Care. 2015 Dec;38(12):2266-73. doi: 10.2337/dc15-0075. Epub 2015 Jul 15. Diabetes Care. 2015. PMID: 26180109 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of Technosphere insulin (TI) and insulin aspart in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: This open-label noninferiority trial compared the change in HbA1c from baseline to week 24 of …
OBJECTIVE: To compare the efficacy and safety of Technosphere insulin (TI) and insulin aspart in patients with type 1 d …
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Akturk HK, et al. Diabetes Technol Ther. 2018 Oct;20(10):639-647. doi: 10.1089/dia.2018.0200. Epub 2018 Sep 15. Diabetes Technol Ther. 2018. PMID: 30207748 Free PMC article.
The primary purpose of this study was to assess both glucose time-in-range (TIR: 70-180 mg/dL) and postprandial glucose excursions (PPGE) in 1-4 h using a real-time continuous glucose monitor (CGM) with Technosphere insulin (TI) versus insulin aspart in patie …
The primary purpose of this study was to assess both glucose time-in-range (TIR: 70-180 mg/dL) and postprandial glucose excursions (PPGE) in …
Technosphere insulin: an inhaled prandial insulin product.
Neumiller JJ, Campbell RK. Neumiller JJ, et al. BioDrugs. 2010 Jun;24(3):165-72. doi: 10.2165/11536700-000000000-00000. BioDrugs. 2010. PMID: 20462282 Review.
Most companies researching and developing pulmonary administration systems for the use of insulin announced the termination of product development following the failure of the first US FDA-approved inhaled insulin product, Exubera. ...Studies with T
Most companies researching and developing pulmonary administration systems for the use of insulin announced the termination of …
Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial.
Raskin P, Heller S, Honka M, Chang PC, Boss AH, Richardson PC, Amin N. Raskin P, et al. Diabetes Obes Metab. 2012 Feb;14(2):163-73. doi: 10.1111/j.1463-1326.2011.01500.x. Epub 2011 Nov 3. Diabetes Obes Metab. 2012. PMID: 21951325 Clinical Trial.
AIMS: Development of inhaled insulin has increased the need to understand its pulmonary safety. This study evaluated pulmonary function changes in diabetes patients receiving inhaled Technosphere Insulin (TI) or usual antidiabetes treatment (usu …
AIMS: Development of inhaled insulin has increased the need to understand its pulmonary safety. This study evaluated pulmonary …
A review of inhaled technosphere insulin.
Neumiller JJ, Campbell RK, Wood LD. Neumiller JJ, et al. Ann Pharmacother. 2010 Jul-Aug;44(7-8):1231-9. doi: 10.1345/aph.1P055. Epub 2010 Jun 1. Ann Pharmacother. 2010. PMID: 20516362 Review.
DATA SYNTHESIS: Technosphere insulin is an inhaled insulin product with a pharmacokinetic profile suitable to meet prandial insulin needs in patients with diabetes. ...The device to administer the insulin is well designed, small, a …
DATA SYNTHESIS: Technosphere insulin is an inhaled insulin product with a pharmacokinetic profile suitable to me …
Inhaled insulin: a breath of fresh air? A review of inhaled insulin.
Santos Cavaiola T, Edelman S. Santos Cavaiola T, et al. Clin Ther. 2014 Aug 1;36(8):1275-89. doi: 10.1016/j.clinthera.2014.06.025. Epub 2014 Jul 17. Clin Ther. 2014. PMID: 25044021 Review.
This review discusses the rationale for pulmonary delivery of insulin, compares previous inhaled insulin products, reviews the literature on the safety and efficacy of a current inhaled insulin formulation under investigation, and comp
This review discusses the rationale for pulmonary delivery of insulin, compares previous inhaled insulin product …
Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
Steiner S, Pfützner A, Wilson BR, Harzer O, Heinemann L, Rave K. Steiner S, et al. Exp Clin Endocrinol Diabetes. 2002 Jan;110(1):17-21. doi: 10.1055/s-2002-19989. Exp Clin Endocrinol Diabetes. 2002. PMID: 11835120 Clinical Trial.

The inhalation of TI was well tolerated. The time to peak action was significantly shorter with both i.v. injection and inhalation, as compared to s.c. (14 +/- 6 min and 39 +/- 36 min vs. 163 +/- 25 min; p < 0.0002 and p < 0.007 (mean +/-

The inhalation of TI was well tolerated. The time to peak action was significantly shorter with both i.v. injection and inh
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.
Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, Petrucci RE, Boss AH, Richardson PC. Rosenstock J, et al. Lancet. 2010 Jun 26;375(9733):2244-53. doi: 10.1016/S0140-6736(10)60632-0. Lancet. 2010. PMID: 20609970 Clinical Trial.
We aimed to assess the efficacy and safety of prandial Technosphere inhaled insulin compared with twice daily biaspart insulin. ...Patients were randomly allocated in a 1:1 ratio to receive 52 weeks' treatment with: prandial Tec
We aimed to assess the efficacy and safety of prandial Technosphere inhaled insulin compared with twice d …
Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin.
Boss AH, Petrucci R, Lorber D. Boss AH, et al. J Diabetes Sci Technol. 2012 Jul 1;6(4):773-9. doi: 10.1177/193229681200600406. J Diabetes Sci Technol. 2012. PMID: 22920801 Free PMC article. Review.
Barriers to the use of prandial insulin regimens include inadequate synchronization of insulin action to postprandial plasma glucose excursions as well as a significant risk of hypoglycemia and weight gain. ...Studies have shown that long-term administrati
Barriers to the use of prandial insulin regimens include inadequate synchronization of insulin action to postprandial p …
17 results
Jump to page
Feedback